Adaptimmune Therapeutics (ADAP) Q3 2024 earnings summary

Executive summary

• Announced a new strategic business plan prioritizing the sarcoma franchise, streamlining operations, and targeting operating break-even by 2027, with a 33% workforce reduction planned by Q1 2025.

• Tecelra, the first FDA-approved engineered cell therapy for solid tumors, launched in August 2024 with nine treatment centers active and expansion planned to 30 by end of 2025.

• Lete-cel pivotal trial met its primary endpoint with a 42% response rate and 10% complete response rate; BLA filing planned for 2025.

• Significant cost reductions and headcount cuts are being implemented, targeting $300 million in savings from 2025–2028.

• Collaboration with Galapagos for uza-cel in head and neck cancer continues, while non-core programs, including ovarian cancer, are being discontinued.

Financial highlights

• Ended Q3 2024 with $186.1 million in total liquidity, including $116.7 million in cash and equivalents.

• Q3 2024 revenue was $40.9 million, up from $7.3 million in Q3 2023, mainly due to Genentech agreement termination and related payments.

• Nine-month revenue rose to $174.8 million from $60.1 million year-over-year, driven by Genentech and Galapagos agreements.

• Net loss for Q3 2024 was $17.6 million, an improvement from $45.6 million loss in Q3 2023; nine-month net profit was $3.4 million versus a $66.0 million loss in the prior year.

• Operating cash outflow for the nine months was $39.0 million, a significant improvement from $126.2 million outflow in the prior year.

Outlook and guidance

• Targeting operating cash flow break-even in 2027, enabled by cost reductions and focused investment.

• Combined U.S. peak year sales for Tecelra and lete-cel projected at $400 million, with lete-cel expected to comprise over 60% of franchise revenue.

• Full ATC network for Tecelra expected to reach 30 centers by end of 2025, covering 80% of eligible patients.

• Lete-cel BLA filing planned for 2025, with commercial launch anticipated to leverage existing infrastructure.

• Management expects current liquidity to fund operations for at least 12 months, but additional capital will be required for long-term operations.